The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

CD19 CAR T-cell immunotherapy plus ibrutinib results in durable responses in R/R CLL

Jul 26, 2019

For patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), who have already failed ibrutinib therapy, CD19-targeted chimeric antigen receptor-engineered T-cells (CAR T) could enable durable response to therapy.

In a pilot phase I/II study ( NCT01865617) conducted by Jordan Gauthier, Fred Hutchinson Cancer Research Center, Seattle, US, and colleagues, the safety and efficacy of ibrutinib plus CD19 CAR T infusion was evaluated in patients with R/R CLL, who had previously failed ibrutinib therapy. The primary goal of this trial was to investigate a potential synergistic association between ibrutinib and CAR T therapy, with the hope of improving outcomes for patients with R/R CLL. Results showed that ibrutinib may improve CAR T cell anti-tumor efficacy and could also reduce the risk of cytokine release syndrome (CRS).

Study design

During the study, 19 patients with R/R CLL were enrolled. The median number of prior therapies was 5 (range, 1–10), with 17 patients (89%) having high-risk cytogenetics (17p deletion and/or complex karyotype and/or 11q abnormalities). All enrolled patients had previously failed ibrutinib treatment.

Ibrutinib (420mg, daily) was administered to patients, along with a defined composition of 2x10 5or 2x10 6/kg CD4 +and CD8 +CD19 CAR T cells after lymphodepletion chemotherapy. Ibrutinib was scheduled from <2 weeks before leukapheresis, and up to >3 months after CAR T infusion.

Key findings

  • Fourteen (74%) patients developed CRS (CRS; Grade 1, n=6, 32%; Grade 2, n=8, 42%)
  • Grade >3 CRS was not observed
  • Five patients developed neurotoxicity (Grade 3, n=5, 26%)
  • One patient died due to presumed ibrutinib-mediated cardiac arrhythmia during Grade 2 CRS
  • Eighteen patients were evaluable for response at restaging 4 weeks after CAR T infusion
  • Patients responding to treatment (International workshop on CLL [iwCLL] criteria): 15 (83%):
    • Complete response with incomplete blood count (CRi): n=4, 22%
    • Partial response (PR): n=11, 61%
  • Ten out of 14 patients (71%) with nodal disease by computed tomography (CT), achieved CR or PR by iwCLL CT criteria
  • Bone marrow disease was eliminated in 13 (72%) patients
  • Eleven (61%) patients were minimal residual disease (MRD) negative by immunoglobin heavy chain (IGH) sequencing
  • One-year overall survival (OS) and progression-free survival (PFS) rates in responders (n=15) were 80% (95% CI, 57–100) and 49% (95% CI, 23–100), respectively
  • Patients who achieved MRD negative bone marrow response by IGH sequencing (n=11) achieved 100% (95% CI, 12–100) and 62% (95% CI, 32–100), one-year OS and PFS rates respectively
    • Nine out of 11 (82%) MRD negative patients were free of disease at last follow-up (median follow-up, 9.5 months)


As results of the study showed that CD19 CAR T-cell therapy combined with ibrutinib led to high rates of durable responses without >grade 3 CRS, the research team concluded that that this combination would be a reasonable choice in patients with R/R CLL. In a previous study, Marie Kersten, from the Academic Medical Center, Amsterdam, NL, found that CAR T therapy lead to durable remissions in patients with DLBCL, and was a feasible treatment option. Below, Renier Brentjens speaks about the latest advances in CAR T-cell therapy.

Expert Opinion

  1. GauthierJ. et al., Durable responses after CD19‐targeted CAR‐T cell immunotherapy with concurrent ibrutinib for CLL after prior ibrutinib failure. Hematol Oncol . 2019 Jun. 37(S2):168-70. DOI: 10.1002/hon.126_2629